Drug side effects linked to reduced recurrence of melanoma

Immune-related adverse events with pembrolizumab ‘reflects drug activity’

Immune-related adverse events during adjuvant therapy with pembrolizumab for stage III melanoma are associated with longer recurrence-free survival, according to a secondary analysis of trial data.